Drs. Christopher Gibbons and Roy Freeman–two of the founders of CND Life Sciences who also serve as senior medical advisors–recently had their research on orthostatic hypotension as an early sign of Parkinson’s disease and dementia highlighted in a New York Times article.
READ THE ARTICLE
CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other related conditions. Operating a CLIA-certified laboratory in Phoenix, Arizona, CND launched the Syn-One Test™ as the world’s first commercially available test to detect, visualize, and quantify the presence of abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is intended to serve as an objective, evidence-based diagnostic tool to aid in the confirmation of synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy body (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through proprietary staining and analysis of three (3) small punch skin biopsies performed and provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field. For more information visit www.cndlifesciences.com.